Compare Merck & Co., Inc. (MRK) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Valero Energy Corporation — how do they compare? Merck & Co., Inc. trades at $142.58 (market cap $351.28B), while Valero Energy Corporation trades at $441 (market cap $127.78B). The key difference: Merck & Co., Inc. is far larger — about 2.7× Valero Energy Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Valero Energy Corporation for 56 Days on average.
| MRK | VLO | |
|---|---|---|
Market Cap | $351.28B | $127.78B |
Volume | 7,969,665 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $156.43 | $443.80 |
52-Week Low | $82.49 | $156.39 |
Typical Hold Time | 98 Days | 56 Days |
Enterprise Value | $398.04B | $131.26B |
Dividend Yield | 2.39% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Valero Energy (VLO) trades at $424.10, up 1.16% today, near its 52-week high. The stock exhibits bullish technical signals with strong moving average alignment and has beaten earnings estimates for three consecutive quarters. Revenue declined to $122.69 billion in 2025, but net income margin improved to 5.17%. Analyst consensus is bullish with a $408.10 price target, and recent news highlights institutional buying and refining margin strength.
Outlook remains positive driven by earnings beats and supportive refining margins, but risks include potential diesel export policy changes and volatile energy markets. The stock's high RSI suggests near-term overbought conditions, yet fundamental improvements and strong cash flow projections for 2026 provide a solid foundation for continued investor interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
